$67.64 Million in Sales Expected for Amyris Inc (AMRS) This Quarter
Equities research analysts expect Amyris Inc (NASDAQ:AMRS) to report $67.64 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Amyris’ earnings. The highest sales estimate is $68.10 million and the lowest is $67.18 million. Amyris reported sales of $32.24 million in the same quarter last year, which would suggest a positive year over year growth rate of 109.8%. The firm is expected to report its next earnings report after the market closes on Thursday, March 15th.
According to Zacks, analysts expect that Amyris will report full year sales of $67.64 million for the current fiscal year, with estimates ranging from $130.90 million to $131.03 million. For the next fiscal year, analysts anticipate that the company will report sales of $0.00 per share. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Amyris.
A number of equities analysts have weighed in on AMRS shares. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Amyris in a research report on Thursday, January 18th. B. Riley started coverage on shares of Amyris in a research report on Thursday, January 25th. They set a “buy” rating and a $8.00 price objective for the company. ValuEngine upgraded shares of Amyris from a “strong sell” rating to a “sell” rating in a research report on Friday, February 23rd. Zacks Investment Research cut shares of Amyris from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Finally, Cowen restated a “hold” rating and set a $4.00 price objective on shares of Amyris in a research report on Wednesday, November 29th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $7.69.
In other Amyris news, insider John Melo sold 10,776 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $4.68, for a total transaction of $50,431.68. Following the completion of the transaction, the insider now directly owns 83,172 shares in the company, valued at $389,244.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 11.30% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Tanaka Capital Management Inc. raised its position in shares of Amyris by 72.0% in the third quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 221,295 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Amyris in the fourth quarter valued at about $451,000. KBC Group NV raised its position in shares of Amyris by 228.4% in the third quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 41,834 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Amyris by 16.3% in the second quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 4,603 shares during the last quarter. Finally, Carl Domino Inc acquired a new stake in shares of Amyris in the third quarter valued at about $182,000. Institutional investors and hedge funds own 22.71% of the company’s stock.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.